^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Kidney Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Kidney Cancer: Principles for systemic therapy for relapse or stage IV disease...Preferred Regimens...Lenvatinib + pembrolizumab (category 1)
